Kyle I. Mentkowski

Kyle I. Mentkowski

Auto-generated profile, based on publicly available information

Kyle I. Mentkowski

Center for Systems Biology, Mass General Brigham and Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KMKyle I. Mentkowski
Kyle I. Mentkowski
JLJennifer K. Lang
Jennifer K. Lang
Injury to the heart results in cardiomyocyte cell death and can lead to pathological remodeling of remaining cells, contributing to heart failure. Despite the therapeutic potential of new drugs and small molecules, there remains a gap in the ability to efficiently deliver cardioprotective agents in a cell specific manner while minimizing nonspecific delivery to other organs. Exosomes derived from cardiosphere-derived cells (CDCs) have been shown to stimulate angiogenesis, induce endogenous cardiomyocyte proliferation and modulate cardiomyocyte apoptosis and hypertrophy. While innately cardioprotective at high doses, unmodified CDC-exosomes demonstrate limited cardiac tropism. To generate an efficient exosomal delivery system that can target cardiomyocytes, we engineered CDCs to express Lamp2b, an exosomal membrane protein, fused to a cardiomyocyte specific peptide (CMP), WLSEAGPVVTVRALRGTGSW. Exosomes isolated from engineered CDCs expressed CMP on their surface and retained their native physical properties. Targeted exosomes resulted in increased uptake by cardiomyocytes, decreased cardiomyocyte apoptosis, and higher cardiac retention following intramyocardial injection when compared with non-targeted exosomes. Importantly, we established a novel targeting system to improve exosomal uptake by cardiomyocytes and laid the foundation for cell-specific exosomal delivery of drug and gene therapies to improve the functional capacity of the heart following both ischemic and non-ischemic injury.

15 March 2018 in The AAPS Journal
Verified
Journal Article
Open access
PDF file
KMKyle I. Mentkowski
Kyle I. Mentkowski
JSJonathan D. Snitzer
Jonathan D. Snitzer
SRSarah Rusnak
Sarah Rusnak
JLJennifer K. Lang
Jennifer K. Lang
Extracellular vesicles (EVs) comprise a heterogeneous group of small membrane vesicles, including exosomes, which play a critical role in intracellular com

24 April 2020 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
KMKyle I. Mentkowski
Kyle I. Mentkowski
AMAsma Mursleen
Asma Mursleen
JSJonathan D. Snitzer
Jonathan D. Snitzer
LELindsey M. Euscher
Lindsey M. Euscher
JLJennifer K. Lang
Jennifer K. Lang
We hypothesized that in the window of therapeutic extracellular vesicle (EV) administration, inflammatory M1 macrophages are likely the primary target of cardiosphere-derived cell (CDC)-derived EVs. The effect of CDC-EVs on this population, however, is currently unknown. In this study, we demonstrate that CDC-derived EVs polarize M1 macrophages to a proangiogenic phenotype dependent on arginase 1 upregulation. These results provide insight into an immunomodulatory mechanism of CDC-EVs in a more physiologically relevant model of post-myocardial infarction (post-MI) macrophage polarization.

2 July 2024 in Circulation
Verified
Journal Article
Closed access
PDF file
JGJana Grune
Jana Grune
GBGeetika Bajpai
Geetika Bajpai
POPervin Tülin Ocak
Pervin Tülin Ocak
EKEva Kaufmann
Eva Kaufmann
KMKyle Mentkowski
Kyle Mentkowski
MNMatthias Nahrendorf
Matthias Nahrendorf
BACKGROUND: Viral infections can cause acute respiratory distress syndrome (ARDS), systemic inflammation, and secondary cardiovascular complications. Lung macrophage subsets change during ARDS, but the role of heart macrophages in cardiac injury during viral ARDS remains unknown. Here we investigate how immune signals typical for viral ARDS affect cardiac macrophage subsets, cardiovascular health, and systemic inflammation. METHODS: We assessed cardiac macrophage subsets using immunofluorescence histology of autopsy specimens from 21 patients with COVID-19 with SARS-CoV-2–associated ARDS and 33 patients who died from other causes. In mice, we compared cardiac immune cell dynamics after SARS-CoV-2 infection with ARDS induced by intratracheal instillation of Toll-like receptor ligands and an ACE2 (angiotensin-converting enzyme 2) inhibitor. RESULTS: In humans, SARS-CoV-2 increased total cardiac macrophage counts and led to a higher proportion of CCR2 + (C-C chemokine receptor type 2 positive) macrophages. In mice, SARS-CoV-2 and virus-free lung injury triggered profound remodeling of cardiac resident macrophages, recapitulating the clinical expansion of CCR2 + macrophages. Treating mice exposed to virus-like ARDS with a tumor necrosis factor α–neutralizing antibody reduced cardiac monocytes and inflammatory MHCII lo CCR2 + macrophages while also preserving cardiac function. Virus-like ARDS elevated mortality in mice with pre-existing heart failure. CONCLUSIONS: Our data suggest that viral ARDS promotes cardiac inflammation by expanding the CCR2 + macrophage subset, and the associated cardiac phenotypes in mice can be elicited by activating the host immune system even without viral presence in the heart.

4 September 2025 in Science
Verified
Journal Article
Closed access
NKNina Kumowski
Nina Kumowski
SPSteffen Pabel
Steffen Pabel
JGJana Grune
Jana Grune
NMNoor Momin
Noor Momin
VNVan K. Ninh
Van K. Ninh
MNMatthias Nahrendorf
Matthias Nahrendorf
Ventricular tachycardia disrupts the heart’s coordinated pump function, leading to sudden cardiac death. Neutrophils, which are recruited in high numbers to the ischemic myocardium, promote these arrhythmias. Comparing neutrophils with macrophages, we found that resistin-like molecule γ ( Retnlg or RELMγ) was the most differentially expressed gene in mouse infarcts. RELMγ is part of a pore-forming protein family that defends the host against bacteria by perforating their membranes. In mice with acute infarcts, leukocyte-specific Retnlg deletion reduced ventricular tachycardia. RELMγ elicited membrane defects that allowed cell exclusion dyes to enter the cardiomyocyte interior and also caused delayed afterdepolarizations and later cardiomyocyte death, both of which are strong arrhythmogenic triggers. Human resistin likewise attacked membranes of liposomes and mammalian cells. We describe how misdirected innate immune defense produces membrane leaks and ventricular arrhythmia.

20 September 2024 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
KMKyle I. Mentkowski
Kyle I. Mentkowski
TTTouba Tarvirdizadeh
Touba Tarvirdizadeh
CMCody A. Manzanero
Cody A. Manzanero
LELisa A. Eagler
Lisa A. Eagler
JLJennifer K. Lang
Jennifer K. Lang
The objective of the study was to assess the therapeutic efficacy of targeting remote zone cardiomyocytes with cardiosphere‐derived cell (CDC) extracellular vesicles (EVs) delivered via intramyocardial and intravenous routes following acute myocardial infarction (MI). Cardiomyocyte (CM) cell death plays a significant role in left ventricular (LV) remodeling and cardiac dysfunction following MI. While EVs secreted by CDCs have shown efficacy in promoting cardiac repair in preclinical models of MI, their translational potential is limited by their biodistribution and requirement for intramyocardial delivery. We hypothesized that engineering the surface of EVs to target cardiomyocytes would enhance their therapeutic efficacy following systemic delivery in a model of acute MI. CDC‐derived EVs were engineered to express a CM‐specific binding peptide (CMP) on their surface and characterized for size, morphology, and protein expression. Mice with acute MI underwent both intramyocardial and intravenous delivery of EVs, CMP‐EVs and placebo in a double‐blind study. LVEF was assessed by echo at 2‐ and 28‐days post‐MI and tissue samples processed for assessment of EV biodistribution and histological endpoints. CMP‐EVs demonstrated superior cardiac targeting and retention when compared with unmodified EVs 24 h post‐MI. Mice treated with IV delivered CMP‐EVs demonstrated a significant improvement in LVEF and a significant reduction in remote zone cardiomyocyte apoptosis when compared with IV delivered non‐targeted EVs at 28‐day post‐MI. Systemic administration of CMP‐EVs improved cardiac function and reduced remote zone cardiomyocyte apoptosis compared with IV‐administered unmodified EVs, demonstrating a strategy to optimize therapeutic EV delivery post‐MI.